AVAI (Avai Bio) Other Long Term Assets: $-0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVAI Avai Bio Inc AVAI
24 GF Score
Price $0.13
! 3 Warning Signs
View Full Analysis

What is Avai Bio Other Long Term Assets?

Avai Bio AVAI -4.14% 24 Other Long Term Assets is $-0.00 Mil as of Dec. 2025. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Avai Bio's other long-term assets for the quarter that ended in Dec. 2025 was $-0.00 Mil.

Avai Bio's quarterly other long-term assets declined from Jun. 2025 ($-0.00 Mil) to Sep. 2025 ($-0.00 Mil) but then increased from Sep. 2025 ($-0.00 Mil) to Dec. 2025 ($-0.00 Mil).

Avai Bio's annual other long-term assets increased from Mar. 2023 ($-0.00 Mil) to Mar. 2024 ($0.00 Mil) but then declined from Mar. 2024 ($0.00 Mil) to Mar. 2025 ($0.00 Mil).

Avai Bio Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Avai Bio's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avai Bio Other Long Term Assets Chart

Avai Bio Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Other Long Term Assets
Get a 7-Day Free Trial 0.00 0.00 -0.00 0.00 0.00

Avai Bio Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 -0.00 -0.00
AVAI
24GF Score
Avai Bio Inc AVAI
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avai Bio Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $-0.00 Mil mean?
Avai Bio (AVAI) has a Other Long Term Assets of $-0.00 Mil as of Dec. 2025. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Avai Bio and its competitors.
Is Avai Bio's Other Long Term Assets too high?
Avai Bio's current Other Long Term Assets is $-0.00 Mil. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's Other Long Term Assets compare to IPM and RCT?
Avai Bio's Other Long Term Assets of $-0.00 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Software company?
A good Other Long Term Assets depends on the Software industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Avai Bio and its competitors. Avai Bio's current Other Long Term Assets is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current Other Long Term Assets of $-0.00 Mil. The current Other Long Term Assets is $-0.00 Mil. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Avai Bio (AVAI), the current Other Long Term Assets is $-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avai Bio Business Description

Address 5348 Vegas Drive, Las Vegas, NV, USA, 89108
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score

Get the complete analysis for AVAI

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price